NCT05375838View on ClinicalTrials.gov

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

December 29, 2022

Study Completion Date

December 29, 2022

Conditions
SARS-CoV-2Influenza
Interventions
BIOLOGICAL

mRNA-1073

Sterile liquid for injection

BIOLOGICAL

mRNA-1010

Sterile liquid for injection

BIOLOGICAL

mRNA-1273

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (14)

13901

Meridian, Binghamton

14609

Rochester Clinical Research Inc, Rochester

33024

Research Centers of America, Hollywood

45219

Meridian, Cincinnati

45246

Meridian, Cincinnati

51106

Meridian, Sioux City

61614

AES - DRS - Optimal Research Illinois - Peoria, Peoria

68701

Meridian, Norfolk

70006

Benchmark Research, Metairie

76135

Benchmark Research, Fort Worth

77065

DM Clinical Research - CyFair, Houston

77081

DM Clinical Research - TCDD, Houston

78705

Benchmark Research, Austin

84121

J Lewis Research, Salt Lake City

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY